Catalent Stock Price, News & Analysis (NYSE:CTLT)

$38.20 -0.31 (-0.80 %)
(As of 11/17/2017 10:50 AM ET)
Previous Close$38.20
Today's Range$38.02 - $38.59
52-Week Range$22.94 - $43.39
Volume760,645 shs
Average Volume852,482 shs
Market Capitalization$5.03 billion
P/E Ratio26.06
Dividend YieldN/A
Beta1.49

About Catalent (NYSE:CTLT)

Catalent logoCatalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NYSE:CTLT
  • CUSIP: N/A
  • Web: www.catalent.com
Debt:
  • Debt-to-Equity Ratio: 2.01%
  • Current Ratio: 2.91%
  • Quick Ratio: 2.49%
Price-To-Earnings:
  • Trailing P/E Ratio: 26.06
  • Forward P/E Ratio: 26.16
  • P/E Growth: 2.4
Sales & Book Value:
  • Annual Sales: $2.0754 billion
  • Price / Sales: 2.45
  • Cash Flow: $2.66 per share
  • Price / Cash: 14.37
  • Book Value: $7.82 per share
  • Price / Book: 4.88
Profitability:
  • Trailing EPS: $0.86
  • Net Income: $109.8 million
  • Net Margins: 5.01%
  • Return on Equity: 23.97%
  • Return on Assets: 5.24%
Misc:
  • Employees: 10,800
  • Outstanding Shares: 132,860,000
 

Frequently Asked Questions for Catalent (NYSE:CTLT)

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How will Catalent's stock buyback program work?

Catalent declared that its Board of Directors has initiated a stock buyback plan on Wednesday, November 15th 2017, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its earnings results on Monday, November, 6th. The company reported $0.21 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to analysts' expectations of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. Catalent's revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.16 earnings per share. View Catalent's Earnings History.

When will Catalent make its next earnings announcement?

Catalent is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Catalent.

Where is Catalent's stock going? Where will Catalent's stock price be in 2017?

8 brokers have issued 12 month target prices for Catalent's stock. Their predictions range from $25.00 to $50.00. On average, they expect Catalent's share price to reach $41.38 in the next twelve months. View Analyst Ratings for Catalent.

What are Wall Street analysts saying about Catalent stock?

Here are some recent quotes from research analysts about Catalent stock:

  • 1. According to Zacks Investment Research, "Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. " (11/6/2017)
  • 2. Jefferies Group LLC analysts commented, "The promise of stability offered by CTLT's diversified revenue stream and LT contracts has been thwarted by FX headwinds, the Beinheim shutdown, and overstocking by DDS segment client. Currency movements are hard to predict or avoid, but management believes the latter two are history. Tuck-in M&A remains a focus to augment mid-single digit revenue growth. We increase estimates and PT slightly. Remain at Hold." (2/27/2017)

Who are some of Catalent's key competitors?

Who are Catalent's key executives?

Catalent's management team includes the folowing people:

  • John R. Chiminski, Chairman of the Board, President, Chief Executive Officer (Age 53)
  • Matthew M. Walsh CPA, Chief Financial Officer, Executive Vice President (Age 51)
  • Aristippos Gennadios Ph.D., President - Softgel Technologies (Age 52)
  • Wetteny Joseph, President - Clinical Supply Services (Age 45)
  • Barry B. Littlejohns, President - Drug Delivery Solutions (Age 51)
  • Steven L. Fasman, Senior Vice President, General Counsel and Corporate Secretary (Age 55)
  • William Downie, Senior Vice President - Global Marketing & Sales (Age 50)
  • Lance Miyamoto, Senior Vice President - Global Human Resources (Age 62)
  • Christine Dolan, Senior Vice President - Product Development (Age 49)
  • Scott Gunther, Senior Vice President - Quality & Regulatory Affairs (Age 50)

Who owns Catalent stock?

Catalent's stock is owned by a number of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (4.86%), Schroder Investment Management Group (3.29%), JPMorgan Chase & Co. (3.24%), Earnest Partners LLC (1.93%), Macquarie Group Ltd. (1.65%) and Brown Advisory Inc. (1.47%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Matthew M Walsh and Sharon Johnson. View Institutional Ownership Trends for Catalent.

Who sold Catalent stock? Who is selling Catalent stock?

Catalent's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Schroder Investment Management Group, Janus Henderson Group PLC, Prudential Financial Inc., Ameriprise Financial Inc., Norris Perne & French LLP MI, Cubist Systematic Strategies LLC and Artemis Investment Management LLP. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski and Sharon Johnson. View Insider Buying and Selling for Catalent.

Who bought Catalent stock? Who is buying Catalent stock?

Catalent's stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Macquarie Group Ltd., Allianz Asset Management GmbH, Three Peaks Capital Management LLC, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Catalent.

How do I buy Catalent stock?

Shares of Catalent can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of Catalent stock can currently be purchased for approximately $38.20.

How big of a company is Catalent?

Catalent has a market capitalization of $5.03 billion and generates $2.0754 billion in revenue each year. The company earns $109.8 million in net income (profit) each year or $0.86 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 Schoolhouse Rd, SOMERSET, NJ 08873-1213, United States. The company can be reached via phone at +1-732-5376200 or via email at [email protected]


MarketBeat Community Rating for Catalent (NYSE CTLT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Catalent (NYSE:CTLT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 3 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $41.38 (8.31% upside)

Consensus Price Target History for Catalent (NYSE:CTLT)

Price Target History for Catalent (NYSE:CTLT)

Analysts' Ratings History for Catalent (NYSE:CTLT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017Piper Jaffray CompaniesBoost Price TargetOverweight$45.00 -> $50.00N/AView Rating Details
10/23/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
9/21/2017Morgan StanleyUpgradeEqual Weight -> Overweight$29.00 -> $48.00HighView Rating Details
9/20/2017Bank of America CorporationReiterated RatingBuy$40.00 -> $45.00LowView Rating Details
9/20/2017Wells Fargo & CompanyBoost Price TargetOutperform$39.00 -> $43.00LowView Rating Details
8/29/2017William BlairReiterated RatingOurperformHighView Rating Details
8/29/2017Jefferies Group LLCReiterated RatingHold$35.00 -> $38.00HighView Rating Details
8/29/2017J P Morgan Chase & CoReiterated RatingBuy$40.00HighView Rating Details
12/1/2016The Goldman Sachs Group, Inc.Initiated CoverageNeutral$25.00N/AView Rating Details
10/20/2016KeyCorpInitiated CoverageOverweight$29.00N/AView Rating Details
10/18/2016StephensInitiated CoverageOverweight$31.00N/AView Rating Details
2/10/2016Deutsche Bank AGLower Price TargetHold$31.00 -> $24.00N/AView Rating Details
12/9/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Catalent (NYSE:CTLT)

Earnings by Quarter for Catalent (NYSE:CTLT)

Earnings History by Quarter for Catalent (NYSE CTLT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
11/6/2017Q1 2018$0.20$0.21$490.75 million$543.90 millionViewN/AView Earnings Details
8/28/2017Q4 2017$0.57$0.65$547.48 million$616.90 millionViewN/AView Earnings Details
5/4/2017Q3 2017$0.36$0.38$470.95 million$532.60 millionViewListenView Earnings Details
2/6/2017Q217$0.27$0.27$474.07 million$483.70 millionViewListenView Earnings Details
11/7/2016Q117$0.13$0.16$430.26 million$442.20 millionViewListenView Earnings Details
8/29/2016Q416$0.53$0.52$498.06 million$532.20 millionViewListenView Earnings Details
5/4/2016Q316$0.31$0.20$425.92 million$438.00 millionViewN/AView Earnings Details
2/9/2016Q216$0.34$0.36$441.99 million$454.90 millionViewN/AView Earnings Details
11/3/2015Q116$0.21$0.14$407.80 million$423.00 millionViewN/AView Earnings Details
9/2/2015Q415$0.58$0.60$496.91 million$510.10 millionViewN/AView Earnings Details
5/5/2015Q3 2015$0.43$0.46$453.25 million$446.60 millionViewN/AView Earnings Details
2/11/2015Q215$0.33$0.44$451.40 million$455.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.20$0.13$411.20 million$418.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalent (NYSE:CTLT)
Current Year EPS Consensus Estimate: $1.46 EPS
Next Year EPS Consensus Estimate: $1.67 EPS

Dividends

Dividend History for Catalent (NYSE:CTLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catalent (NYSE CTLT)

Insider Ownership Percentage: 1.70%
Institutional Ownership Percentage: 95.65%
Insider Trades by Quarter for Catalent (NYSE:CTLT)
Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Insider Trades by Quarter for Catalent (NYSE CTLT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Christine DolanSVPSell1,594$38.75$61,767.50View SEC Filing  
8/1/2017Christine DolanSVPSell745$34.85$25,963.25View SEC Filing  
4/25/2017Sharon JohnsonInsiderSell9,160$29.00$265,640.00View SEC Filing  
3/20/2017John R. ChiminskiInsiderSell73,819$28.62$2,112,699.78View SEC Filing  
2/15/2017Donald E. Morel, Jr.DirectorBuy10,000$29.27$292,700.00View SEC Filing  
9/9/2016Blackstone Management AssociatMajor ShareholderSell17,100,705$23.58$403,234,623.90View SEC Filing  
6/9/2016Blackstone Management AssociatMajor ShareholderSell8,785,539$24.51$215,333,560.89View SEC Filing  
5/27/2016Matthew M WalshInsiderSell21,197$28.85$611,533.45View SEC Filing  
8/19/2015John R ChiminskiInsiderSell38,505$33.81$1,301,854.05View SEC Filing  
8/17/2015John R ChiminskiInsiderSell35,550$33.80$1,201,590.00View SEC Filing  
7/20/2015John R ChiminskiInsiderSell33,081$29.40$972,581.40View SEC Filing  
7/6/2015John R ChiminskiInsiderSell33,828$29.34$992,513.52View SEC Filing  
6/11/2015Blackstone Management AssociatMajor ShareholderSell1,844,963$28.13$51,898,809.19View SEC Filing  
6/8/2015Blackstone Management AssociatMajor ShareholderSell12,299,753$28.13$345,992,051.89View SEC Filing  
4/1/2015Scott HoultonInsiderSell16,253$30.61$497,504.33View SEC Filing  
3/27/2015Stephen LeonardInsiderSell31,005$30.13$934,180.65View SEC Filing  
2/17/2015Scott HoultonInsiderSell14,538$27.50$399,795.00View SEC Filing  
2/13/2015Scott HoultonInsiderSell1,400$28.28$39,592.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catalent (NYSE:CTLT)

Latest Headlines for Catalent (NYSE CTLT)

Source:
DateHeadline
Catalent (CTLT) Announces Share Buyback PlanCatalent (CTLT) Announces Share Buyback Plan
www.americanbankingnews.com - November 15 at 11:55 AM
Finish Line and Zions slide while Movado and Lockheed riseFinish Line and Zions slide while Movado and Lockheed rise
marketbeat.com - August 29 at 4:36 PM
Catalent beats Street 3Q forecastsCatalent beats Street 3Q forecasts
marketbeat.com - May 4 at 7:58 PM
CATALENT, INC. Files SEC form 8-K/A, Change in Directors or Principal OfficersCATALENT, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
biz.yahoo.com - February 9 at 5:02 PM
Catalent (CTLT) Q2 2017 Results - Earnings Call TranscriptCatalent (CTLT) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - February 7 at 2:39 AM
Catalent (CTLT) Falls Ahead of EarningsCatalent (CTLT) Falls Ahead of Earnings
www.baystreet.ca - February 6 at 9:38 PM
CTLT Crosses Above Average Analyst Target - NasdaqCTLT Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - February 2 at 4:59 PM
Catalent, Inc. Announces Second Quarter Fiscal Year 2017 ... - Business Wire (press release)Catalent, Inc. Announces Second Quarter Fiscal Year 2017 ... - Business Wire (press release)
www.businesswire.com - January 19 at 5:50 PM
Bullish Two Hundred Day Moving Average Cross - CTLTBullish Two Hundred Day Moving Average Cross - CTLT
www.nasdaq.com - December 13 at 5:14 PM

Social Media

Financials

Chart

Catalent (NYSE CTLT) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.